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MicroRNAs (miRNAs) are small non-coding RNAs which function as endogenous silencers
of various target genes. miRNAs are expressed in a tissue-speciﬁc manner and playing
important roles in cell proliferation, apoptosis, and differentiation during mammalian devel-
opment. Links between miRNAs and the initiation and progression of human diseases
including cancer are becoming increasingly apparent. Recent studies have revealed that
some miRNAs such as miR-9, miR-29 family, and miR-34 family are differentially expressed
in Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease. These miRNAs are
also reported to act as tumor suppressors during human carcinogenesis. In this review,
we discuss about miRNAs which are important in the molecular pathogenesis of both can-
cer and neurodegeneration. Cancer and neurodegenerative disorder may be inﬂuenced by
common miRNA pathways that regulate differentiation, proliferation, and death of cells.
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THE BIOGENESIS OF miRNA
MicroRNAs (miRNAs) are∼22 nucleotide (nt) non-coding RNAs
that can post-transcriptionally downregulate the expression of
various target genes. Currently, ∼1500 human miRNAs have
been identiﬁed in the human genome, each of which poten-
tially controls hundreds of target genes. As shown in Figure 1,
miRNA genes are generally transcribed from transcription start
sites (TSSs) by RNA polymerase II (pol II) to form primary tran-
scripts (pri-miRNAs). Pol II-transcribed pri-miRNAs are capped
with 7-methylguanosine and are polyadenylated. The nuclear
RNase III enzyme Drosha and its co-factor DGCR8 process pri-
miRNAs into ∼60-nt precursor miRNAs (pre-miRNAs), which
form an imperfect stem-loop structure. Pre-miRNAs are trans-
ported into the cytoplasm by exportin 5 and are subsequently
cleaved by Dicer into mature miRNAs, which are then loaded into
the RNA-induced silencing complex (RISC). The miRNA/RISC
complex downregulates speciﬁc gene products by translational
repression via binding to partially complementary sequences in
the 3′-untranslated regions (UTRs) of the target mRNAs or by
directing mRNA degradation via binding to perfectly comple-
mentary sequences (He and Hannon, 2004). One strand of the
miRNA duplex, which is derived from pre-miRNA, remains sta-
bly associated with RISC and guides it mainly, but not exclusively,
to the 3′-UTR of the target mRNAs. Targeting can also occur in
the 5′-UTR of the target mRNAs (Lewis et al., 2005; Lytle et al.,
2007; Qin et al., 2010). In addition, a recent study has revealed
that miRNAs are not only able to downregulate speciﬁc gene
products but also can activate the expression of a target gene
(Vasudevan et al., 2007). miRNAs are expressed in a tissue-speciﬁc
manner and play important roles in cell proliferation, apopto-
sis, and differentiation during mammalian development. Links
between miRNAs and the development of human malignancies
are becoming increasingly apparent (Calin and Croce, 2006, 2007;
Saito et al., 2009a).
miRNAs AS TUMOR SUPPRESSORS AND ONCOGENES
The ﬁnding that predicted targets of miRNAs are enriched for
genes involved in transcriptional regulation, cell proliferation,
and apoptosis implies that aberrant expression of miRNAs might
contribute to the initiation and progression of human can-
cer. Onco-miRNAs and suppressor-miRNAs can represent two
different looks of the same gene, behaving as oncogenes or
tumor suppressors depending on tissue type and speciﬁc targets
(Fabbri et al., 2007b). Calin et al. (2004) examined the mapping
of 186 human miRNAs and compared their locations to genomic
regions involved in cancers. They found that miRNA genes are
frequently located at fragile sites which include loss of heterozy-
gosity (LOH), ampliﬁcation, and breakpoints, indicating that
these miRNAs may be dysregulated in human cancers. Some
miRNAs are downregulated in various human cancers, which
suggests that they may function as tumor suppressors. let-7 is
downregulated in lung cancer and targets a critical oncogene RAS
(Johnson et al., 2005). miR-15 and miR-16 are downregulated in
chronic lymphocytic leukemia and target an antiapoptotic gene
BCL2 (Cimmino et al., 2005). miR-143 and miR-145 are down-
regulated in colorectal and breast cancer (Michael et al., 2003;
Iorio et al., 2005).
On the other hand, some miRNA genes are overexpressed in
cancers, indicating that they may have roles as oncogenes and
accelerate the development of cancer. miR-155 and its host gene
BIC are highly expressed in several types of B cell lymphoma (Eis
et al., 2005). High expression of precursor miR-155 is reported
in children with Burkitt lymphoma (Metzler et al., 2004). More-
over, recent studies have shown that miR-155 is overexpressed
in several types of human solid tumors including breast, colon,
and lung cancer (Iorio et al., 2005; Volinia et al., 2006; Yanaihara
et al., 2006). These studies strongly suggest that miR-155 is an
oncogenic miRNA. The miR-17-92 cluster, which is located on
chromosome 13q31, is activated by the oncogene c-Myc which
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FIGURE 1 |The biogenesis of miRNA.
is an important regulator of cell growth and is often mutated
or ampliﬁed in human cancers. The miR-17-92 cluster is highly
expressed in breast, colon, lung, pancreatic, and prostate can-
cer, as well as in B cell lymphoma (Hayashita et al., 2005; He
et al., 2005; Volinia et al., 2006). c-Myc binding upregulates the
transcription factor E2F1 and twomiRNAs in the miR-17-92 clus-
ter, miR-17-5p and miR-20a, target E2F1 (O’Donnell et al., 2005).
This suggests that there is a negative feedback loop involving
c-Myc, E2F1, miR-17-5p, and miR-20a whereby c-Myc induces
expression of E2F1 and the post-transcriptional repressors of
E2F1, miR-17-5p, and miR-20a. Volinia et al. (2006) showed that
miR-20a also targets the tumor suppressor transforming growth
factor beta receptor 2 (TGFBR2). Chan et al. (2005) showed
that miR-21 is strongly overexpressed in the highly malignant
brain tumor glioblastoma. They also revealed that knockdown
of miR-21 in cultured glioblastoma cells induces activation of
caspases and leads to increased apoptotic cell death, suggesting
that miR-21 is an antiapoptotic factor in human glioblastoma
cells. miR-21 is upregulated in breast, colon, lung, pancre-
atic, prostate, and stomach cancer (Iorio et al., 2005; Volinia
et al., 2006). Moreover, miR-21 is highly overexpressed in human
cholangiocarcinoma and modulates gemcitabine-induced apop-
tosis by directly altering PTEN expression (Meng et al., 2007).
Taken together, these ﬁndings indicate that miRNAs have critical
roles in the mechanism of human carcinogenesis and that aber-
rant expression of miRNAs may contribute to the development of
human cancer.
miRNAs IN CANCERS AND NEURODEGENERATIVE
DISORDERS
Cancer and neurodegenerative disease may be inﬂuenced by com-
mon signaling pathways regulating the balance of cell survival
and death. Recent studies suggest that the molecular machinery
involved inmaintaining neural function in neurodegenerative dis-
ease may be shared with oncogenic pathways. p53 is one of the
most extensively studied proteins because of its role in cancer
prevention, and has been recently shown to be involved in aging
and Alzheimer’s disease (AD). The observation that aging and AD
interfere with proteins controlling duplication and cell cycle may
lead to the speculation that, in senescent neurons, aberrations in
proteins generally dealing with cell cycle control and apoptosis
could affect neuronal plasticity and functioning rather than cell
duplication (Lanni et al., 2012).
Recent studies have revealed that some miRNAs are aberrantly
expressed in the brains of patients with neurodegenerative diseases
such as AD, Parkinson’s disease (PD) and Huntington’s disease
(HD; Junn and Mouradian, 2012). This suggests that miRNAs
play critical roles in neurodegeneration as well as cancer. Speciﬁc
miRNAs may regulate the expression of their target proteins that
are involved in the development of neurodegenerative diseases.
Interestingly, several miRNAs differentially expressed in neurode-
generative diseases such as miR-9, miR-29 family, and miR-34
family are considered to be potential tumor suppressor miRNAs
(Table 1). Cancer and neurodegenerative disorder may be inﬂu-
enced by common miRNA pathways that regulate differentiation,
proliferation and death of cells.
miR-9
Aberrant DNA methylation at CpG island promoters of tumor
suppressor genes is one of the most important mechanisms of
human carcinogenesis. Recent studies have shown that miR-9 is
silenced by aberrant CpG island methylation in various human
cancers including breast cancer, cancer metastasis, gastric can-
cers, and lung cancers, suggesting that miR-9 is a potential tumor
suppressor miRNA (Lehmann et al., 2008; Lujambio et al., 2008;
Du et al., 2012; Heller et al., 2012).
Huntington’s disease is an autosomal dominant neurodegen-
erative disease caused by CAG trinucleotide repeat expansion
in huntingtin, which encodes Huntingtin (Htt). Patients with
HD experience abnormal motor movements, cognitive decline,
and psychiatric disturbances that frequently result in premature
death. Although Htt is ubiquitously expressed, patients with HD
show predominantly CNS manifestations. One putative mecha-
nism underlying the transcriptional changes is aberrant cellular
distribution of the transcriptional repressor RE1-silencing tran-
scription factor (REST). REST expression is highest in pluripotent
stem cells and decreases upon restriction to neural progeni-
tor cells and subsequently to neurons. REST silences neuronal
gene expression in non-neuronal cells. In mature, healthy neu-
rons, REST is expressed at low levels and primarily sequestered
in the cytoplasm in part through interaction with Htt. How-
ever, in patients with HD, mutant Htt fails to bind REST,
enabling its nuclear translocation. In the nucleus, REST can
bind RE1 consensus sequences and recruit corepressors includ-
ing mSin3, REST corepressor 1 (CoREST), and methyl CpG
binding protein 2 (MeCP2) to inactivate neuron-speciﬁc genes
(Zuccato et al., 2003).
Packer et al. (2008) have reported that levels of several miRNAs
with upstream RE1 sites are decreased in HD patient cortices rel-
ative to healthy controls. One of these, miR-9 and miR-9*, which
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Table 1 | miRNAs differentially expressed in cancers and neurodegenerative disorders.
miRNA Expression in cancers Expression in neurodegenerative
disorders
Target genes Reference
miR-9 Silenced in breast cancer and
cancer metastasis by DNA
methylation
Decreased in Huntington’s disease REST/CoREST Chan et al. (2005),
O’Donnell et al. (2005),
Lanni et al. (2012)
miR-29a/29b-1 Decreased in various cancers Decreased in Alzheimer’s disease MCL1, DNMT3A,
DNMT3B, BACE1
Lujambio et al. (2008),
Du et al. (2012),
Junn and Mouradian (2012)
miR-34b/34c Silenced in colon cancer and
cancer metastasis by DNA
methylation
Decreased in Parkinson’s disease MET, CCNE2, CDK4,
CDK6
Fabbri et al. (2007a),
Mott et al. (2007)
decreased early in HD, are processed from the same primary tran-
script from three genomic loci (miR-9-1, miR-9-2, and miR-9-3).
miR-9-1 and miR-9-3 both have upstream RE1 sequences that
can be occupied by REST. Interestingly, miR-9/miR-9*, targets
two components of the REST complex: miR-9 targets REST and
miR-9* targets CoREST. These data provide evidence for a double
negative feedback loop between the REST silencing complex and
miR-9/miR-9* (Packer et al., 2008).
miR-29 FAMILY
A recent study has revealed that miR-29 family (miR-29a, miR-
29b, and miR-29c) target the de novo DNA methyltransferases
DNMT3A and DNMT3B and expression levels of miR-29 fam-
ily were suppressed in lung cancer. The reduced expression of
the miR-29 family induced overexpression of DNMT3A and
DNMT3B, resulting in aberrant DNA methylation in lung can-
cer (Fabbri et al., 2007a). In addition, Mott et al. (2007) have
demonstrated thatMCL1, encoding an antiapoptotic BCL2 family
protein, is one of the targets of miR-29 family, and that miR-29
miRNAs regulate apoptosis by targeting MCL1. These ﬁndings
suggest that miR-29 family act as tumor suppressors by targeting
DNMT3A, DNMT3B, and MCL1.
Mutations in the APP and PSEN genes cause amyloid β
(Aβ) accumulation and familial AD. However, little is known
about the mechanisms that contribute to Aβ accumulation in
the vast majority of sporadic AD cases. BACE1/β-secretase cleav-
age of APP is the rate-limiting step for Aβ peptide production.
Increased BACE1 expression is observed in patients with spo-
radic AD, and several mechanisms for this upregulation have
been proposed. A link between BACE1 levels, Aβ load, and AD
pathology has been reported, suggesting that increased BACE1
expression is indeed an important risk factor for sporadic AD
(Li et al., 2004).
Hebert et al. (2008) investigated changes in miRNA expression
proﬁles of sporadic AD patients and found that several miR-
NAs potentially involved in the regulation of APP and BACE1
expression appeared to be decreased in their brain. They have
shown that miR-29a, miR-29b-1, and miR-9 can regulate BACE1
expression as their targets. The miR-29a/b-1 cluster was signif-
icantly decreased in AD patients displaying overexpression of
BACE1 protein. Similar correlations between expression of this
cluster and BACE1 were found during brain development and in
primary neuronal cultures. They provided evidence for a poten-
tial causal relationship between miR-29a/b-1 expression and Aβ
generation in a cell culture model and proposed that loss of spe-
ciﬁc miRNAs can contribute to increased BACE1 and Aβ levels
in sporadic AD (Hebert et al., 2008). A recent study has shown
that miR-29c also regulates BACE1 protein expression (Zong
et al., 2011). These ﬁndings suggest that miR-29 family regulate
BACE1 expression and play important roles in the pathogenesis
of AD.
miR-34b/34c
miR-34a was identiﬁed as a target of p53 and induces a G (He
and Hannon, 2004) cell cycle arrest, senescence, and apopto-
sis (He et al., 2007; Tazawa et al., 2007). miR-34a expression is
silenced in several types of cancer including pancreatic cancer
due to aberrant CpG methylation of its promoter. Re-expression
of miR-34a in a pancreatic cancer cell line induced senescence
and cell cycle arrest by targeting CDK6, indicating that miR-34a
represents a tumor suppressor gene which is inactivated by CpG
methylation in pancreatic cancer (Lodygin et al., 2008). miR-34b
and miR-34c are also reported to be direct targets of p53 and
silenced by aberrant CpG island methylation in colorectal cancer
(Toyota et al., 2008).
Parkinson’s disease is the secondmost common neurodegener-
ative disorder, characterized by the presence of protein inclusions
or Lewy bodies and a progressive loss of dopaminergic neurons
in the midbrain. Minones-Moyano et al. (2011) have evaluated
miRNA expression deregulation in PD brain samples. miRNA
expression proﬁles revealed decreased expression of miR-34b and
miR-34c in brain areas with variable neuropathological affectation
at clinical stages of PD.Downregulation of miR-34b/c was detected
in pre-motor stages of PD. Depletion of miR-34b or miR-34c in
differentiated SH-SY5Y dopaminergic neuronal cells resulted in
a moderate reduction in cell viability that was accompanied by
alteredmitochondrial function and dynamics, oxidative stress and
reduction in total cellular adenosine triphosphate content. More-
over, they have shown that DJ1 and Parkin are indirect targets of
miR-34b/c. miR-34b/c downregulation induced a decrease in the
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expression of DJ1 and Parkin, two proteins associated to famil-
ial forms of PD. DJ1 and Parkin expression was reduced in PD
brain samples displaying strongmiR-34b/c downregulation. These
data suggest that early deregulation of miR-34b/c, which are direct
targets of p53, in PD triggers downstream transcriptome alter-
ations underlying mitochondrial dysfunction and oxidative stress,
which ultimately compromise cell viability (Minones-Moyano
et al., 2011). As mentioned above, p53 is also involved in the
pathogenesis of AD. These ﬁndings indicate that p53 may play
important roles in the initiation and progression of both AD and
PD via different miRNA-mediated mechanisms.
miRNA-MEDIATED THERAPY FOR CANCER AND
NEURODEGENERATIVE DISEASE
The distinct connection between aberrant expression of miRNAs
and human diseases suggests that miRNAs could be therapeu-
tic targets. Epigenetic changes such as DNA methylation and
histone modiﬁcation modulate chromatin structure and gene
expression in mammalian development and in human diseases
(Egger et al., 2004). Many miRNAs are expressed in a tissue- and
tumor-speciﬁc manner, implying that some miRNAs are sub-
ject to epigenetic control. We have recently shown that ∼5% of
humanmiRNAs are upregulatedmore than threefold by treatment
of T24 bladder cancer cells with the DNA demethylating agent
5-aza-2′-deoxycytidine (5-Aza-CdR) and the histone deacetylase
(HDAC) inhibitor 4-phenylbutyric acid (PBA). In particular,
miR-127, which is embedded in a CpG island, is remarkably
induced by a decrease inDNAmethylation levels and an increase in
active histone marks around the promoter region of the miR-127
gene. In addition, activation of miR-127 by epigenetic treat-
ment induced downregulation of its target oncogene BCL6 (Saito
et al., 2006). We have also demonstrated that treatment of gas-
tric cancer cells with 5-Aza-CdR and PBA induces activation
of miR-512-5p which is located at Alu repeats on chromosome
19. Activation of miR-512-5p by epigenetic treatment induces
suppression of MCL1, resulting in apoptosis of gastric cancer
cells (Saito et al., 2009b). These results indicate that chromatin
remodeling by epigenetic treatment can directly modulate expres-
sion of miRNAs that are involved in the pathogenesis of cancer
and neurodegenerative disease. In addition, recent study has
shown that locked-nucleic-acid-modiﬁed oligonucleotide (LNA-
antimiR) effectively antagonizes speciﬁc miRNAs and could be
used to silence miRNAs that are overexpressed in human diseases
(Elmen et al., 2008). Because the link between miRNAs and can-
cer and neurodegeneration has only just begun to be understood,
there could be a large number of critical miRNAs and their target
genes. Further studies are necessary to identify the speciﬁc miR-
NAs that could be therapeutic targets and/or molecular markers
for human cancers and neurodegenerative disorders.
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